You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

FUROSCIX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Furoscix, and when can generic versions of Furoscix launch?

Furoscix is a drug marketed by Scpharmaceuticals and is included in one NDA. There are three patents protecting this drug.

This drug has twenty-four patent family members in fifteen countries.

The generic ingredient in FUROSCIX is furosemide. There are twenty-two drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the furosemide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Furoscix

A generic version of FUROSCIX was approved as furosemide by MYLAN on October 29th, 1986.

  Try a Trial

Summary for FUROSCIX
Drug patent expirations by year for FUROSCIX
Drug Prices for FUROSCIX

See drug prices for FUROSCIX

Recent Clinical Trials for FUROSCIX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of Texas Southwestern Medical CenterPhase 2
scPharmaceuticals, Inc.Phase 2
scPharmaceuticals, Inc.Phase 1

See all FUROSCIX clinical trials

Pharmacology for FUROSCIX
Drug ClassLoop Diuretic
Physiological EffectIncreased Diuresis at Loop of Henle
Anatomical Therapeutic Chemical (ATC) Classes for FUROSCIX

US Patents and Regulatory Information for FUROSCIX

FUROSCIX is protected by three US patents.

Patents protecting FUROSCIX

Pharmaceutical formulations for subcutaneous administration of furosemide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Pharmaceutical formulations for subcutaneous administration of furosemide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE

Pharmaceutical formulations for subcutaneous administration of furosemide
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: USE OF A LIQUID FORMULATION COMPRISING FUROSEMIDE TO TREAT CONGESTION DUE TO FLUID OVERLOAD (EDEMA) IN ADULTS WITH NYHA CLASS II/III CHRONIC HEART FAILURE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scpharmaceuticals FUROSCIX furosemide SOLUTION;SUBCUTANEOUS 209988-001 Oct 7, 2022 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for FUROSCIX

See the table below for patents covering FUROSCIX around the world.

Country Patent Number Title Estimated Expiration
World Intellectual Property Organization (WIPO) 2014165660 ⤷  Try a Trial
Mexico 367165 FORMULACIONES FARMACÉUTICAS PARA ADMINISTRACIÓN SUBCUTÁNEA DE FUROSEMIDA. (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE.) ⤷  Try a Trial
Singapore 10201709388Q PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE ⤷  Try a Trial
Japan 6677779 ⤷  Try a Trial
South Korea 20160014592 퓨로세마이드의 피하 투여용 약학 제형 (PHARMACEUTICAL FORMULATIONS FOR SUBCUTANEOUS ADMINISTRATION OF FUROSEMIDE) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.